Suchergebnisse - "Dejnirattisai, Wanwisa"

PubPharm (16)

1

COVID-19 vaccination, risk-compensatory behaviours, and contacts in the UK

enthalten in: Scientific reports | 2023

von Buckell, J. | Jones, J. | Matthews, P. | +65

2

Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UK

enthalten in: Nature communications | 2023

von Wei, J. | Matthews, P. | Stoesser, N. | +75

3

Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens

enthalten in: Med (New York, N.Y.) | 2023

von Moore, S. | Kronsteiner, B. | Longet, S. | +62

4

Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules : exploratory analyses of Com-COV, a randomised control trial

enthalten in: The Lancet. Respiratory medicine | 2022

von Shaw, R. | Liu, X. | Stuart, A. | +82

5

SARS-CoV-2 antibody trajectories after a single COVID-19 vaccination with and without prior infection

enthalten in: Nature communications | 2022

von Wei, J. | Matthews, P. | Stoesser, N. | +76

6

Potent cross-reactive antibodies following Omicron breakthrough in vaccinees

enthalten in: Cell | 2022

von Nutalai, R. | Zhou, D. | Tuekprakhon, A. | +33

7

Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK : Three month analyses of the COV-BOOST trial

enthalten in: The Journal of infection | 2022

von Liu, X. | Munro, A. | Feng, S. | +56

CommentIn: J Infect. 2023 Feb;86(2):154-225. - PMID 36509358

8

The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies

enthalten in: EBioMedicine | 2022

von Spencer, A. | Morris, S. | Ulaszewska, M. | +23

9

Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001) : a phase 4, non-inferiority, single blind, randomised study

enthalten in: Lancet (London, England) | 2022

von Costa Clemens, S. | Weckx, L. | Clemens, R. | +44

CommentIn: Lancet. 2022 Feb 5;399(10324):496-497. - PMID 35074137

10

Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine

enthalten in: Cell | 2021

von Payne, R. | Longet, S. | Austin, J. | +133